フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
LAVAL, Québec, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq:...
Call to be held on Thursday, August 11th at 1:00 PM Eastern Time LAVAL, Quebec, Aug. 02, 2022 (GLOBE...
LAVAL, Quebec, July 27, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST...
LAVAL, Québec, June 22, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq:...
Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, June 21, 2022 (GLOBE NEWSWIRE...
LAVAL, Quebec, June 16, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST...
LAVAL, Québec, June 14, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq:...
Bioavailability of IV GTX-104 compared favorably with the oral formulation of nimodipine, and no serious...
LAVAL, Québec, April 25, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”...
LAVAL, Quebec, March 25, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq:...
LAVAL, Québec, March 22, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”...
LAVAL, Quebec, March 09, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq:...
LAVAL, Québec, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq:...
Provides updates on key milestones: GTX-104 PK study remains on track for results to be reported in the first...
LAVAL, Quebec, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約